HOME
RESEARCH
How to BH3 Profile
Current Members
Alumni
PUBLICATIONS
News Archive
Jobs
SUPPORT US
CONTACT
Letai Lab Anthem
The Letai Lab - Targeting Cancer Cell Death
Publications
BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia
Blood Advances, 2023 February
Letai Lab Author(s): Anthony Letai
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
Clinical Cancer Research, 2022 December 15
Letai Lab Author(s): Jeremy Ryan, Anthony Letai
Collateral deletion of the mitochondrial AAA+ ATPase ATAD1 sensitizes cancer cells to proteasome
dysfunction.
eLife, 2022 November 21
Letai Lab Author(s): Jeremy Ryan, Anthony Letai
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia
Nature Cancer, 2022 May
Letai Lab Author(s): Salma Parvin, Anthony Letai
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
Blood Advances, 2021 December 28
Letai Lab Author(s): Jeremy Ryan, Danielle Potter, Geoffrey Fell, Thelma Mashaka, Anthony Letai
Activation of Notch and Myc Signaling via B-cell-Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia
Cancer Research, 2021 December 15
Letai Lab Author(s): Salma Parvin, Anthony Letai
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening
Cancer Discovery, 2021 October
Letai Lab Author(s): Patrick Bhola, Anthony Letai
An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML
Cancer Discovery, 2021 September 16
Letai Lab Author(s): Jeremy Ryan, Thelma Mashaka, Anthony Letai
Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment
Nature Cancer, 2021 July
Letai Lab Author(s): Salma Parvin, Anthony Letai
Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma
Blood Advances, 2021 May 11
Letai Lab Author(s): Stephan Bohl, Anthony Letai
Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling
Cancers, 2021 February 28
Letai Lab Author(s): Jeremy Ryan, Anthony Letai
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity
Nature Cancer, 2021 January
Letai Lab Author(s): Veerle Daniels, Anthony Letai
An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities
Blood Cancer Discovery, 2021 January
Letai Lab Author(s): Jeremy Ryan, Anthony Letai
Aneuploidy increases resistance to chemotherapeutics by antagonizing cell division
Proceedings of the National Academy of Sciences of the United States of America, 2020 December 1
Letai Lab Author(s): Anthony Letai, Jeremy Ryan
Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer
Breast Cancer Research, 2020 November 30
Letai Lab Author(s): Veerle Daniels, Anthony Letai
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a Phase 1b study.
American Journal of Hematology, 2020 October 29
Letai Lab Author(s): Anthony Letai
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes.
Blood Advance, 2020 October 27
Letai Lab Author(s): Salma Parvin, Anthony Letai
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
New England Journal of Medicine, 2020 August 13
Letai Lab Author(s): Jacqueline S. Garcia, Anthony Letai
Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition.
Cancer Discovery, 2020 October 10
Letai Lab Author(s): Salma Parvin, Anthony Letai
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to reinduction chemotherapy
American Journal of Hematology, 2019 Dec 5
Letai Lab Author(s): Jacqueline S. Garcia, Shruti Bhatt, Geoffrey Fell, Adam S. Sperling, Binyam Yilma, Anthony Letai
Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies.
Nature Communication, 2019 Nov 14
Letai Lab Author(s): Joan Montero, Anthony Letai
DNA Methyltransferase Inhibition Overcomes Diphthamide Pathway Deficiencies Underlying CD123-targeted Treatment Resistance
Journal of Clinical Investigations, 2019 Nov 1
Letai Lab Author(s): Joan Montero, Anthony Letai
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
Cancer Cell, 2019 Oct 14
Letai Lab Author(s): Joan Montero, Anthony Letai
BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics
Cell Death and Differentiation, 2019 July 22
Letai Lab Author(s): Anthony Letai, Jeremy Ryan, Mariana Villalobos-Ortiz, Thelma Mashaka
Patterns of substrate affinity, competition and degradation kinetics underlie biological activity of thalidomide analogs.
Blood. 2019 May 1
Letai Lab Author(s): Anthony Letai, Shruti Bhatt, Elyse Olesinski
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins.
Nature Rev Mol Cell Biol. 2019 Mar 20
Letai Lab Author(s): Anthony Letai
MCL1 and DEDD Promote Urothelial Carcinoma Progression.
Mol Cancer Res. 2019 Feb 18
Letai Lab Author(s): Anthony Letai
Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas.
Blood. 2019 Feb 7
Letai Lab Author(s): Anthony Letai, Jennifer Crombie
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
Blood. 2019 Jan 3
Letai Lab Author(s): Anthony Letai
PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia.
J Exp Med. 2018 Dec 3
Letai Lab Author(s): Anthony Letai
Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL
Blood. 2018 Oct 15
Letai Lab Author(s): Anthony Letai, Jeremy Ryan, Mariana Villalobos-Ortiz
Splicing
modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies
JCI Insight. 2018 Oct 4
Letai Lab Author(s): Anthony Letai
Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance
EMBO Reports. 2018 Sep
Letai Lab Author(s): Anthony Letai
PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells
Blood. 2018 Sep 13
Letai Lab Author(s): Anthony Letai, Shruti Bhatt
BCL-2 inhibition in AML: an unexpected bonus?
Blood. 2018 Sep 6
Letai Lab Author(s): Anthony Letai
Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy
BMC Gastroenterology. 2018 Jun 22
Letai Lab Author(s): Anthony Letai, Jeremy Ryan
Statins enhance efficacy of venetoclax in blood cancers
Science Translational Medicine. 2018 Jun 13
Letai Lab Author(s): Anthony Letai, Shruti Bhatt
Targeting B-Cell Lymphoma 2: A Lethal Shortcut in Del(17p) Chronic Lymphocytic Leukemia.
J Clin Oncol. 2018 May 22
Letai Lab Author(s): Anthony Letai
MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia
Cancer Discovery. 2018 Apr 18
Letai Lab Author(s): Patrick Bhola, Anthony Letai
Diminished apoptotic priming and ATM signalling confer a survival advantage onto aged haematopoietic stem cells in response to DNA damage
Nature Cell Biology. 2018 Mar 12
Letai Lab Author(s): Anthony Letai
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
The Lancet Oncology. 2018 Feb 19
Letai Lab Author(s): Anthony Letai
ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase Inhibitors
Cancer Research. 2018 Feb 15
Letai Lab Author(s): Danielle Potter, Anthony Letai
Iterative optimization yields Mcl-1-targeting stapled peptides with selective cytotoxicity to Mcl-1-dependent cancer cells
Proceedings of the National Academy of Sciences of the United States of America. 2018 Jan 30
Letai Lab Author(s): Anthony Letai, Joan Montero
Targeted apoptosis of myofibroblasts with BH3 mimetic ABT-263 reverses established fibrosis
Science Translational Medicine. 2017 Dec 13
Letai Lab Author(s): Jeremy Ryan, Patrick Bhola, Joan Montero, Anthony Letai
Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax
Cancer Discovery. 2017 Dec
Letai Lab Author(s): Anthony Letai
Why do BCL-2 inhibitors work and where should we use them in the clinic?
Cell Death & Differentiation. 2017 Oct 27
Letai Lab Author(s): Anthony Letai, Joan Montero
Inhibition of USP10 induces degradation of oncogenic FLT3
Nature Chemical Biology. 2017 Oct 2
Letai Lab Author(s): Shruti Bhatt, Anthony Letai
Functional precision cancer medicine- moving beyond pure genomics
Nature Medicine. 2017 Sept 8
Letai Lab Author(s): Anthony Letai
Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1
Elife. 2017 Jun 8
Letai Lab Author(s): Jeremy Ryan, Anthony Letai
Synergistic interactions with PI3K inhibition that induce apoptosis
Elife. 2017 May 31
Letai Lab Author(s): Patrick Bhola, Anthony Letai
Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection
Elife. 2017 Apr 20
Letai Lab Author(s): Anthony Letai
Inhibition of MAPKinase pathway sensitizes thyroid cancer cells to ABT-737 induced apoptosis
Cancer Lett. 2017 Jun 1
Letai Lab Author(s): Anthony Letai, Kris Sarosiek
Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia
Leukemia. 2017 Jan 23
Letai Lab Author(s): Jing Deng, Anthony Letai, Matt Davids
Blastic
Plasmacytoid Dendritic Cell Neoplasm is Dependent on BCL-2 and Sensitive to Venetoclax
Cancer Discov. 2016 Dec 16
Letai Lab Author(s): Joan Montero, Leah Hogdal, Matt Davids, Anthony Letai
Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance
Cell Rep. 2016 Dec 20
Letai Lab Author(s): Kris Sarosiek, Anthony Letai
Discovery and biological characterization of potent Myeloid Cell Leukemia-1 (Mcl-1) inhibitors
FEBS Letters. 2016 Nov 11
Letai Lab Author(s): Leah Hogdal, Anthony Letai
Genomic evolution and chemoresistance in germ cell tumors
Nature. 2016 Nov 2
Letai Lab Author(s): Jennifer Guerriero, Anthony Letai
Cristae remodeling causes acidification detected by integrated graphene sensor during mitochondrial outer membrane permeabilization
Sci Rep. 2016 Oct 27
Letai Lab Author(s): Anthony Letai
Spatial proximity to fibroblasts impacts molecular features and therapeutic sensitivity of breast cancer cells influencing clinical outcomes
Cancer Res. 2016 Sep 26
Letai Lab Author(s): Jennifer Guerriero, Anthony Letai
Functionally identifiable, apoptosis-insensitive subpopulations determine chemoresistance in AML
J Clin Invest. 2016 Oct 3
Letai Lab Author(s): Patrick Bhola, Jeremy Ryan, Leah Hogdal, Anthony Letai
Efficacy and biological correlates of response in a phase 2 study of venetoclax monotherapy in patients with acute myelogenous leukemia
Cancer Discov. 2016 Oct
Letai Lab Author(s): Leah Hogdal, Anthony Letai
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
Nature communications. 2016 May 20
Letai Lab Author(s): Kris Sarosiek, Matt Davids, Anthony Letai
Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid
leukaemia cells
Oncotarget. 2016 Apr 15
Letai Lab Author(s): Jeremy Ryan, Joan Montero, Anthony Letai
The public repository of xenografts enables discovery and randomized phase II-like trials in mice
Cancer Cell. 2016 Apr 11
Letai Lab Author(s): Joan Montero, Matt Davids, Jackie Garcia, Anthony Letai
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53 independent mechanism
Blood. 2016 Jun 23
Letai Lab Author(s): Jing Deng, Matt Davids, Anthony Letai
iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry
Biol Chem. 2016 Jul 1
Letai Lab Author(s): Jeremy Ryan, Joan Montero, Anthony Letai
BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics
Leukemia. 2016 Mar
Letai Lab Author(s): Jennifer Guerriero, Triona Chonghaile, Anthony Letai
Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines
Oncotarget. 2016 Mar 8
Letai Lab Author(s): Jeremy Ryan, Anthony Letai
Rapid Optimization of Mcl-1 Inhibitors using stapled peptide libraries including non-natural side chains
ACS Chem Biol. 2016 May 20
Letai Lab Author(s): Jeremy Ryan, Anthony Letai
Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL
Cell Death Dis. 2016 Feb 4
Letai Lab Author(s): Kris Sarosiek, Anthony Letai
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Nature. 2016 Jan 21
Letai Lab Author(s): Anthony Letai
MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199
Cell Rep. 2015 Dec 29
Letai Lab Author(s): Triona Chonghaile, Anthony Letai
Targeting the miR-221-222/PUMA/BAK/BAX pathway abrogates dexamethasone resistance in Multiple Myeloma
Cancer Res. 2015 Oct 15
Letai Lab Author(s): Triona Chonghaile, Anthony Letai
Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice
Leukemia. 2015 Jul 23
Letai Lab Author(s):Joan Montero, Anthony Letai
Direct and immune-mediated cytotoxicity of interleukin-21 contributes to anti-tumor effects in mantle cell lymphoma
Blood. 2015 Sep 24
Letai Lab Author(s): Shruti Bhatt, Kris Sarosiek, Anthony Letai
Activity of the type II JAK2 inhibitor CHZ868 in B Cell acute lymphoblastic leukemia.
Cancer Cell. 2015 Jul 13
Letai Lab Author(s): Jeremy Ryan, Anthony Letai
Drug- Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Cell. 2015 Feb 27
Letai Lab Author(s): Joan Montero, Kris Sarosiek, Joe DeAngelo, Jeremy Ryan, Anthony Letai
Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL depenedence and sensitivity to ABT-199.
Cancer Discovery. 2014 Jul 3
Letai Lab Author(s): Triona Chonghaile, Jeremy Ryan, Anthony Letai
APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction.
Dev Cell. 2014 May 27
Letai Lab Author(s): Jing Deng, Anthony Letai
Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation
Haematologica. 2014 May 27
Letai Lab Author(s): Jeremy Ryan, Matthew Davids, Anthony Letai
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS mutant lung cancers
Cancer Research. 2014 March 27
Letai Lab Author(s): Anthony Letai
Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells
Cell Death Differ. 2014 Mar 28
Letai Lab Author(s): Leah Hogdal, Anthony Letai
Selective BCL-2 Inhibition by ABT-199 Causes On Target Cell Death in Acute Myeloid Leukemia
Cancer Discovery. 2013 Dec 17
Letai Lab Author(s): Leah Hogdal, Jeremy Ryan, Anthony Letai
Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis.
Apoptosis. 2013 Nov 12
Letai Lab Author(s): Anthony Letai
Mitochondria: gatekeepers of response to chemotherapy.
Trends in Cell Biology. 2013 Sep 26
Letai Lab Author(s): Kristopher Sarosiek, Triona Chonghaile, Anthony Letai
BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response.
Molecular Cell. 2013 Oct 01
Letai Lab Author(s): Kristopher Sarosiek, Joan Montero, Luv Patel, Anthony Letai
BH3 profiling in whole cells by fluorimeter or FACS.
Cell Death and Differentiation. 2013 Apr 24
Letai Lab Author(s): Jeremy Ryan, Anthony Letai
p53 regulates a non-apoptotic death induced by ROS.
Cell Death and Differentiation. 2013 May 25
Letai Lab Author(s): Joan Montero, Anthony Letai
High mitochondrial priming sensitizes hESCs to DNA-damage-induced apoptosis.
Cell Stem Cell. 2013 Aug 21
Letai Lab Author(s): Jeremy Ryan, Anthony Letai
BCL-2 inhibition: stemming the tide of myeloid malignancies.
Cell Stem Cell. 2013 Mar 12
Letai Lab Author(s): Leah Hogdal, Anthony Letai
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
British Journal of Haematology. 2013 Feb 5
Letai Lab Author(s): Joan Montero, Anthony Letai
Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer.
Breast Cancer Research. 2013 Nov 1
Letai Lab Author(s): Jing Deng, Anthony Letai
Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.
Cell. 2012 Oct 16
Letai Lab Author(s): Thanh-Trang Vo, Jeremy Ryan, Anthony Letai
BH3-only proteins are part of a regulatory network that control the sustained signalling of the unfolded protein response sensor IRE1alpha.
EMBO Journal. 2012 Apr 19
Letai Lab Author(s): Anthony Letai
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
Cancer Discovery. 2012 Sep 11
Letai Lab Author(s): Joan Montero, Anthony Letai
BCL2 suppresses PARP1 function and nonapoptotic cell death.
Cancer Research. 2012 Jun 13
Letai Lab Author(s): Matthew Davids, Jeremy Ryan, Anthony Letai
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia.
Blood. 2012 Sep 8
Letai Lab Author(s): Matthew Davids, Jing Deng, Anthony Letai
P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment.
Blood. 2011 Nov 19
Letai Lab Author(s): Triona Chonghaile, Anthony Letai
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.
Science. 2011 Oct 29
Letai Lab Author(s): Triona Chonghaile, Kristopher Sarosiek, Thanh-Trang Vo, Jeremy Ryan, Anu Tammareddi, Victoria Del Gaizo Moore, Jing Deng, Anthony Letai
The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance.
Cell Death & Disease. 2011 Jun 24
Letai Lab Author(s): Jeremy Ryan, Anthony Letai
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.
Blood. 2010 Mar 4
Letai Lab Author(s): Derek Yecies, Nicole Carlson, Jing Deng, Ph.D.
Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes.
PNAS. 2010 Jul 10
Letai Lab Author(s): Jeremy Ryan, Joslyn Brunelle, Anthony Letai
Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells.
Cell Death & Differentiation. 2010 May 1
Letai Lab Author(s): Ozgur Kutuk, Anthony Letai
The landscape of somatic copy-number alteration across human cancers.
Nature. 2010 Feb 19
Letai Lab Author(s): Derek Yecies, Anthony Letai
Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression.
Blood. 2009 Aug 5
Letai Lab Author(s): Nicole Carlson, Anthony Letai
MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts.
Journal of Cell Biology. 2009 Dec 2
Letai Lab Author(s): Joslyn Brunelle, Jeremy Ryan, Derek Yecies, Anthony Letai
Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release.
Human Molecular Genetics. 2009 Aug 15
Letai Lab Author(s): Anthony Letai
Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737.
Cancer Research. 2008 Oct 3
Letai Lab Author(s): Ozgur Kutuk, Anthony Letai
BIM and other BCL-2 family proteins exhibit cross-species conservation of function between zebrafish and mammals.
Cell Death and Differentiation. 2007 Dec 18
Letai Lab Author(s): Anabelle Flanagan, Jeremy Ryan, Anthony Letai
BH3 domains define selective inhibitory interactions with BHRF-1 and KSHV BCL-2.
Cell Death and Differentiation. 2007 Dec 18
Letai Lab Author(s): Anabelle Flanagan, Anthony Letai
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.
Blood. 2007 Dec 7
Letai Lab Author(s): Victoria Del Gaizo Moore, Anthony Letai
Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.
Cancer Research. 2007 Dec 20
Letai Lab Author(s): Jing Deng, Nicole Carlson, Anthony Letai
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.
Cancer Cell. 2007 Aug 19
Letai Lab Author(s): Jing Deng, Nicole Carlson, Anthony Letai
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.
Journal of Clinical Investigation. 2007 Jan 4
Letai Lab Author(s): Victoria Del Gaizo Moore, Michael Certo, Anthony Letai
BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma.
Oncogene. 2006 Mar 29
Letai Lab Author(s): Anthony Letai
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.
Cancer Cell. 2006 May 16
Letai Lab Author(s): Michael Certo, Victoria Del Gaizo Moore, Anthony Letai
An inhibitor of Bcl-2 family proteins induces regression of solid tumours.
Nature. 2005 May 20
Letai Lab Author(s): Anthony Letai
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
Cancer Cell. 2005 Nov 16
Letai Lab Author(s): Anthony Letai
Antiapoptotic BCL-2 is required for maintenance of a model leukemia.
Cancer Cell. 2004 Sep 24
Letai Lab Author(s): Anthony Letai
Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.
Nature. 2003 Dec 12
Letai Lab Author(s): Anthony Letai
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.
Cancer Cell. 2002 Sep 21
Letai Lab Author(s): Anthony Letai
The importance of intramolecular ion pairing in intermediate filaments.
PNAS. 1995 Jan 3
Letai Lab Author(s): Anthony Letai
Disease severity correlates with position of keratin point mutations in patients with epidermolysis bullosa simplex.
PNAS. 1993 Apr 15
Letai Lab Author(s): Anthony Letai
Do the ends justify the mean? Proline mutations at the ends of the keratin coiled-coil rod segment are more disruptive than internal mutations.
Journal of Cell Biology. 1992 Mar 1
Letai Lab Author(s): Anthony Letai
The genetic basis of epidermolytic hyperkeratosis: a disorder of differentiation-specific epidermal keratin genes.
Cell. 1992 Sep 4
Letai Lab Author(s): Anthony Letai
Point mutations in human keratin 14 genes of epidermolysis bullosa simplex patients: genetic and functional analyses.
Cell. 1991 Sep 20
Letai Lab Author(s): Anthony Letai
Pancreas-graft immunogenicity and pretreatment with anti-class II monoclonal antibodies.
Diabetes. 1989 Jan 1
Letai Lab Author(s): Anthony Letai
Specificity in formation of triple-stranded nucleic acid helical complexes: studies with agarose-linked polyribonucleotide affinity columns.
Biochemistry. 1988 Jan 27
Letai Lab Author(s): Anthony Letai
Lab Published:
BH3 profiling as pharmacodynamic biomarker for the activity of BH3 mimetics
Haematologica, 2023 October 26
Letai Lab Author(s): Rongqing 'Aaron' Pan, Jeremy Ryan, Anthony Letai
Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia
Blood Advances, 2023 October 10
Letai Lab Author(s): Salma Parvin, Aditi Aryal, Anthony Letai
Sequential apoptotic and multiplexed proteomic evaluation of single cancer cells
Science Advances, 2023 June 23
Letai Lab Author(s): Emmalyn Lecky, Atreyi Mukherji, Rebecca German, Gabriella Antonellis, Michael Yorsz, Kelley McQueeney, Jeremy Ryan, Patrick Bhola, Anthony Letai
Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma
Nature Communications, 2023 May 20
Letai Lab Author(s): Danielle Potter, Ruochen Du, Stephan Bohl, Anthony Letai
Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cells
Cell Death and Disease, 2023 April 13
Letai Lab Author(s): Alexandra Pourzia, Michael Olson, Aditi Aryal, Jeremy Ryan, Anthony Letai
Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis
Cell, 2022 April 28
Letai Lab Author(s): Rongqing Pan, Jeremy Ryan, Anthony Letai,
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations
Cancer Cell, 2022 January 10
Letai Lab Author(s): Anthony Letai, Patrick Bhola
Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer
Cell Death and Disease, 2021 July 27
Letai Lab Author(s): Danielle Potter, Ruochen Du, Patrick Bhola, Raphael Bueno, Anthony Letai
Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics
Science Signaling June 2021
Letai lab Author(s): Veerle Daniels, Kelley McQueeney, Salma Parvin, Danielle Potter, Geoffrey G. Fell, Vinícius G. Ferreira, Binyam Yilma, Rajat Gupta ,Patrick D. Bhola, Kristopher A. Sarosiek , Anthony Letai
Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration
PNAS, June 2021
Letai Lab Author(s): Jeremy Ryan, Anthony Letai
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Cancer Cell, 2020 December
Letai Lab Author(s): Shruti Bhatt, Marissa Pioso, Elyse Olesinski, Binyam Yilma, Jeremy Ryan, Thelma Mashaka, Stephan Bohl, Jacqueline Garcia, Anthony Letai
High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumor
Science Signalling, 2020 June 16
Letai Lab Author(s): Patrick Bhola, Eman Ahmed, Jennifer Guerriero, Emily Su, Elizaveta Lavrova, Jing Ni, Marissa Pioso, Kelley McQueeney, Jeremy Ryan, Anthony Letai
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to reinduction chemotherapy
American Journal of Hematology, 2019 Dec 5
Letai Lab Author(s): Jacqueline S. Garcia, Shruti Bhatt, Geoffrey Fell, Adam S. Sperling, Binyam Yilma, Anthony Letai
BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics
Cell Death and Differentiation, 2019 July 22
Letai Lab Author(s): Anthony Letai, Jeremy Ryan, Mariana Villalobos-Ortiz, Thelma Mashaka
Class IIa HDAC inhibition reduces breast tumors and metastases via anti-tumor macrophages
Nature. 2017 Jan 19
Letai Lab Author(s): Jennifer Guerriero, Alaba Sotayo, Holly Ponichtera, Jessica Castrillon, Alex Pourzia, Sara Schad, Anthony Letai
Developmental regulation of mitochondrial apoptosis by c-Myc governs age- and tissue-specific sensitivity to cancer therapeutics
Cancer Cell. 2017 Jan 9
Letai Lab Author(s): Kris Sarosiek, Cameron Fraser, Patrick Bhola, Jeremy Ryan, Jing Deng, Anthony Letai
iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry
Biol Chem. 2016 Jul 1
Letai Lab Author(s): Jeremy Ryan, Joan Montero, Anthony Letai
Functionally identifiable, apoptosis-insensitive subpopulations determine chemoresistance in AML
J Clin Invest. 2016 Oct 3
Letai Lab Author(s): Patrick Bhola, Jeremy Ryan, Leah Hogdal, Anthony Letai
Drug- Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Cell. 2015 Feb 27
Letai Lab Author(s): Joan Montero, Kris Sarosiek, Joe DeAngelo, Jeremy Ryan, Anthony Letai
Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL depenedence and sensitivity to ABT-199.
Cancer Discovery. 2014 Jul 3
Letai Lab Author(s): Triona Chonghaile, Jeremy Ryan, Anthony Letai
Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer.
Breast Cancer Research. 2013 Nov 1
Letai Lab Author(s): Jing Deng, Anthony Letai
p53 regulates a non-apoptotic death induced by ROS.
Cell Death and Differentiation. 2013 May 25
Letai Lab Author(s): Joan Montero, Anthony Letai
BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response.
Molecular Cell. 2013 Oct 01
Letai Lab Author(s): Kristopher Sarosiek, Joan Montero, Luv Patel, Anthony Letai
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia.
Blood. 2012 Sep 8
Letai Lab Author(s): Matthew Davids, Jing Deng, Anthony Letai
Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.
Cell. 2012 Oct 16
Letai Lab Author(s): Thanh-Trang Vo, Jeremy Ryan, Anthony Letai
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.
Science. 2011 Oct 29
Letai Lab Author(s): Triona Chonghaile, Kristopher Sarosiek, Thanh-Trang Vo, Jeremy Ryan, Anu Tammareddi, Victoria Del Gaizo Moore, Jing Deng, Anthony Letai
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.
Blood. 2010 Mar 4
Letai Lab Author(s): Derek Yecies, Nicole Carlson, Jing Deng, Ph.D.
Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes.
PNAS. 2010 Jul 10
Letai Lab Author(s): Jeremy Ryan, Joslyn Brunelle, Anthony Letai
MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts.
Journal of Cell Biology. 2009 Dec 2
Letai Lab Author(s): Joslyn Brunelle, Jeremy Ryan, Derek Yecies, Anthony Letai
Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737.
Cancer Research. 2008 Oct 3
Letai Lab Author(s): Ozgur Kutuk, Anthony Letai
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.
Journal of Clinical Investigation. 2007 Jan 4
Letai Lab Author(s): Victoria Del Gaizo Moore, Michael Certo, Anthony Letai
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.
Cancer Cell. 2007 Aug 19
Letai Lab Author(s): Jing Deng, Nicole Carlson, Anthony Letai
BIM and other BCL-2 family proteins exhibit cross-species conservation of function between zebrafish and mammals.
Cell Death and Differentiation. 2007 Dec 18
Letai Lab Author(s): Anabelle Flanagan, Jeremy Ryan, Anthony Letai
BH3 domains define selective inhibitory interactions with BHRF-1 and KSHV BCL-2.
Cell Death and Differentiation. 2007 Dec 18
Letai Lab Author(s): Anabelle Flanagan, Anthony Letai
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.
Blood. 2007 Dec 7
Letai Lab Author(s): Victoria Del Gaizo Moore, Anthony Letai
Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.
Cancer Research. 2007 Dec 20
Letai Lab Author(s): Jing Deng, Nicole Carlson, Anthony Letai
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.
Cancer Cell. 2006 May 16
Letai Lab Author(s): Michael Certo, Victoria Del Gaizo Moore, Anthony Letai
The Letai Lab - Targeting Cancer Cell Death